Chordate Medical has been notified of the granting of additional patent protection for headache treatment in the United StatesChordate Medical Holding AB (Publ.) announces that the US Patent Office has issued a decision that they intend to grant Chordates patent application US 16 / 938,383 from 2020. The patent application concerns the treatment of headaches with the focus on protecting the companys technology Kinetic Oscillation Stimulation (K.O.S). The granting of the application means that a third American patent is added to a growing patent family focused on headache treatment that the company has built since 2011.
"One of the three pillars of our strategy to build the company value for our shareholders is to pursue our patent strategy. The intellectual property defence of our technology in support of the business development is an essential part of what we consider core values in the company", says Anders Weilandt, CEO of Chordate Medical. For more information, please contact:
Anders Weilandt, CEO
[email protected]
Cell: +46 733-874277 N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medicals share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, [email protected].
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 